Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review

COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies

“…On 17 November 2021 Galmiche et al [ 41 ] published a systematic review of studies, in which COVID-19 VE in IC populations in real-world settings was assessed in four of the included studies. The other studies included in this systematic review assessed COVID-19 vaccine immunogenicity in IC populations (N = 157 studies) and one study assessed vaccine efficacy in a clinical trial setting [ 41 ].…”

“…On 17 November 2021 Galmiche et al [ 41 ] published a systematic review of studies, in which COVID-19 VE in IC populations in real-world settings was assessed in four of the included studies. The other studies included in this systematic review assessed COVID-19 vaccine immunogenicity in IC populations (N = 157 studies) and one study assessed vaccine efficacy in a clinical trial setting [ 41 ]. Three of the four studies that assessed COVID-19 VE in IC populations included in this systematic review, Tenforde et al [ 18 ], Khan & Mahmud [ 20 ], and Chodick et al [ 24 ], have already been included in our targeted literature review.…”

Detailed characterization of hospitalized patients infected with the Omicron variant of SARS‐CoV‐2

“…While it is well documented that vaccines are effective against the Omicron variant [ 3 ], patients in our cohort hospitalized for Omicron were significantly more likely to be vaccinated. This likely reflects the overall high rate of vaccination in our surrounding area and the large number of patients we observed hospitalized with Omicron who were at high risk for more severe illness due to underlying immunosuppression, respiratory illness, or morbid obesity [ 4 ].…”

Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination

“…There are some studies on the effect of anti-CD20 therapies on the COVID-19 vaccine efficacy among immunosuppressed patients. The results of these studies demonstrate that the level of anti-SARS-CoV-2 IgG, and also vaccine efficacy, were decreased in patients with malignancies, solid organ transplantation or inflammatory rheumatic diseases [68,69]. With regard to these facts, some authors suggest consideration of a 4-6 month time-window before and after vaccination due to the induction of rapid and prolonged (up to 24 weeks) B-cell depletion and attenuated humoral immune responsiveness by anti-CD20 antibodies and also differential kinetics of B-cells repopulation in immunocompromised patients.…”